Geode Capital Management
DFTX

Geode Capital Management’s Definium Therapeutics DFTX Stock Holding History

Geode Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171M Buy
3,644,813
+1,149,414
+46% +$28.4M 0.01% 890
2026
Q1 		$47.2M Buy
2,495,399
+162,461
+7% +$2.76M ﹤0.01% 1522
2025
Q4 		$31.2M Buy
2,332,938
+508,237
+28% +$6.29M ﹤0.01% 1763
2025
Q3 		$21.5M Buy
1,824,701
+91,247
+5% +$851K ﹤0.01% 1966
2025
Q2 		$11.3M Buy
1,733,454
+66,663
+4% +$438K ﹤0.01% 2283
2025
Q1 		$9.75M Sell
1,666,791
-56,297
-3% -$403K ﹤0.01% 2307
2024
Q4 		$12M Buy
1,723,088
+45,386
+3% +$312K ﹤0.01% 2253
2024
Q3 		$9.55M Buy
1,677,702
+162,933
+11% +$1.13M ﹤0.01% 2411
2024
Q2 		$10.9M Buy
1,514,769
+1,125,365
+289% +$9.84M ﹤0.01% 2268
2024
Q1 		$3.66M Buy
389,404
+11,489
+3% +$65.5K ﹤0.01% 2864
2023
Q4 		$1.38M Buy
377,915
+6,602
+2% +$19.9K ﹤0.01% 3218
2023
Q3 		$1.16M Buy
371,313
+303
+0.1% +$1.25K ﹤0.01% 3261
2023
Q2 		$1.32M Buy
371,010
+30,955
+9% +$107K ﹤0.01% 3248
2023
Q1 		$1.08M Buy
340,055
+58,384
+21% +$194K ﹤0.01% 3310
2022
Q4 		$619K Buy
+281,671
New +$782K ﹤0.01% 3567
2022
Q3 		– Sell
-13,410
Closed -$129K – 5036
2022
Q2 		$129K Sell
13,410
-174,769
-93% -$2.21M ﹤0.01% 4481
2022
Q1 		$3.13M Sell
188,179
-5,737
-3% -$99.5K ﹤0.01% 3037
2021
Q4 		$4.01M Sell
193,916
-286
-0.1% -$9.13K ﹤0.01% 3012
2021
Q3 		$6.79M Buy
194,202
+13,396
+7% +$579K ﹤0.01% 2728
2021
Q2 		$9.36M Buy
+180,806
New +$9.49M ﹤0.01% 2504

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management's DFTX Position: Q2 2026 in Review

Geode Capital Management increased its Definium Therapeutics (DFTX) stake by 46% in Q2 2026, buying an estimated $28.4M and bringing the position to 3,644,813 shares worth $171M. The position accounts for 0.01% of the portfolio, ranked #890.

Geode Capital Management first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Geode Capital Management held 3,644,813 shares of Definium Therapeutics worth $171M as of Q2 2026.
  • Geode Capital Management bought 1,149,414 Definium Therapeutics shares in Q2 2026, an estimated $28.4M.
  • Definium Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #890 holding.
  • Geode Capital Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.